# The biochemical dynamics of the glycogen phosphatase laforin directly impact brain metabolism

**Authors:** M.Kathryn Brewer, Katherine J. Donohue, Pankaj K. Singh, Madushi Raththagala, Zoe R. Simmons, Jeremiah L. Wayne, Sheng Li, Rosa Viana, Dyann M. Segvich, Christopher J. Contreras, Alex R. Cantrell, Pascual Sanz, Ramon C. Sun, Craig W. Vander Kooi, Peter J. Roach, Anna DePaoli-Roach, Matthew S. Gentry

PMC · DOI: 10.1016/j.jbc.2025.111097 · 2025-12-22

## TL;DR

This study explores how the glycogen phosphatase laforin affects brain metabolism and its role in a fatal childhood disease.

## Contribution

The study reveals that laforin's phosphatase activity is crucial for normal brain metabolism and disease prevention.

## Key findings

- LCS protein shows higher phosphate and glucan binding compared to wild-type laforin.
- LCS mice exhibit distinct and significant global metabolic perturbations in the brain.
- Altered laforin dynamics lead to aberrant protein retention in the brain of LCS knock-in mice.

## Abstract

Laforin is the only known glycogen phosphatase. Mutations in the laforin gene lead to the fatal childhood dementia and progressive myoclonic epilepsy known as Lafora disease (LD). A hallmark of LD is aberrant, cytoplasmic, glycogen-like aggregates known as Lafora bodies. Surprisingly, recent reports indicate that overexpression of a phosphatase-deficient laforin mutant, with the catalytic cysteine mutated to serine (LCS), prevented the formation of Lafora bodies in a laforin KO mouse model. This finding led to questions regarding the biological relevance of laforin phosphatase activity and its role in LD etiology. In this study, we defined the in vitro and in vivo effects of the LCS mutation. LCS protein lacks catalytic activity but exhibits significantly higher binding to phosphate and long glucan chains compared with WT laforin. In addition, LCS exhibits altered dynamics via hydrogen–deuterium exchange mass spectrometry and interacts more robustly with its binding partners malin and protein targeting to glycogen. We demonstrate that these altered dynamics result in aberrant retention of the LCS protein in the brain of the LCS knock-in mouse model, compared with laforin levels in WT mice. To examine the metabolic consequences of these biophysical changes, we compared the brain metabolomic phenotypes of LCS mice to WT and laforin KO mice. Furthermore, LCS mice display a distinct and significant global perturbation in metabolism. These results indicate a key signaling role for glycogen phosphorylation in glycogen metabolism, revealing an important biological role for laforin catalytic phosphatase activity.

## Linked entities

- **Genes:** EPM2A (epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)) [NCBI Gene 421611], NHLRC1 (NHL repeat containing E3 ubiquitin protein ligase 1) [NCBI Gene 378884]
- **Proteins:** EPM2A (epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)), LCS1 (lymphedema-cholestasis syndrome 1), NHLRC1 (NHL repeat containing E3 ubiquitin protein ligase 1)
- **Diseases:** Lafora disease (MONDO:0009697), progressive myoclonic epilepsy (MONDO:0020074)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Nhlrc1 (NHL repeat containing 1) [NCBI Gene 105193] {aka B230309E09Rik, EPM2B}, Epm2a (epilepsy, progressive myoclonic epilepsy, type 2 gene alpha) [NCBI Gene 13853] {aka TG-B, Tg(TcraK,TcrbK)TG-BFlv}, Ppp1r3c (protein phosphatase 1, regulatory subunit 3C) [NCBI Gene 53412] {aka PTG, Ppp1r5}
- **Diseases:** LD (MESH:D020192), LCS (MESH:C535330), myoclonic epilepsy (MESH:D004831), dementia (MESH:D003704)
- **Chemicals:** hydrogen (MESH:D006859), phosphate (MESH:D010710), deuterium (MESH:D003903), glycogen (MESH:D006003), glucan (MESH:D005936)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** cysteine mutated to serine

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12834914/full.md

---
Source: https://tomesphere.com/paper/PMC12834914